Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) Chief Financial Officer Ryan Preblick executed a sale of 36,000 shares of the company’s common stock on June 8, 2026. The transaction was priced at $37.70 per share, resulting in total proceeds of $1,357,200. The timing of the sale is particularly notable given Indivior’s recent market performance. Over the past year, the company’s stock has appreciated by nearly 180%. As of the reporting date, the stock is trading at $38.26, placing it close to its 52-week high of $41. Despite this significant rally, analysis indicates that the stock remains undervalued relative to its Fair Value estimate, suggesting that there is still potential for upside.
The divestment was carried out in accordance with a Rule 10b5-1 trading plan that Preblick established on March 6, 2026. This type of plan allows executives to pre-arrange trades in advance, helping to ensure compliance with insider trading regulations. Following this transaction, Preblick’s direct ownership of Indivior Pharmaceuticals common stock stands at 284,751 shares.
In other recent corporate developments, Indivior reported financial results for the first quarter of 2026 that exceeded both earnings and revenue expectations. The company achieved an earnings per share of $0.96, which significantly outpaced the forecasted $0.66, representing a 45.45% surprise. Furthermore, Indivior’s revenue reached $317 million, surpassing the anticipated $270.93 million by 17%. These results underscore the company’s strong financial performance during this period.
Additionally, Indivior announced a $175 million accelerated share repurchase agreement with Barclays Bank PLC. This buyback is part of the company’s existing $400 million share repurchase program. The announcement reflects Indivior’s confidence in its long-term strategy and cash flow generation, as well as its commitment to disciplined capital allocation.